Disease-corrected haematopoietic progenitors from Fanconi anemia induced pluripotent stem cells

The generation of induced pluripotent stem (iPS) cells by ectopic expression of a defined set of factors1-5 has enabled the derivation of patient-specific pluripotent cells and provided valuable experimental platforms to model human disease6-8. Patientspecific iPS cells are also thought to hold grea...

Descripción completa

Detalles Bibliográficos
Autores: Raya, Ángel|||0000-0003-2189-9775, Rodríguez-Pizà, Ignasi, Guenechea, Guillermo, Vassena, Rita|||0000-0002-0846-0365, Navarro Ordóñez, Susana|||0000-0002-0764-5384, Barrero, María José, Consiglio, Antonella, Castellà, Maria, Río, Paula, Sleep, Eduard, González, Federico, Tiscornia, Gustavo, Garreta, Elena|||0000-0002-1071-9794, Aasen, Trond|||0000-0003-0763-2695, Veiga, Anna|||0000-0002-0943-9904, Verma, Inder M., Surralles, Jordi|||0000-0002-4041-7519, Bueren, Juan|||0000-0002-3228-7013, Izpisúa Belmonte, Juan Carlos
Tipo de recurso: artículo
Fecha de publicación:2009
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:68792
Acceso en línea:https://ddd.uab.cat/record/68792
https://dx.doi.org/urn:doi:10.1038/nature08129
Access Level:acceso abierto
Palabra clave:Fanconi anemia (FA)
PREI 2010
Descripción
Sumario:The generation of induced pluripotent stem (iPS) cells by ectopic expression of a defined set of factors1-5 has enabled the derivation of patient-specific pluripotent cells and provided valuable experimental platforms to model human disease6-8. Patientspecific iPS cells are also thought to hold great therapeutic potential, although direct evidence for this is still lacking. Here we show that somatic cells from Fanconi anemia (FA) patients, upon correction of the genetic defect, can be reprogrammed to pluripotency to generate patient-specific iPS cells. These cell lines appear indistinguishable from human embryonic stem cells and iPS cells from healthy individuals in colony morphology, growth properties, expression of pluripotencyassociated transcription factors and surface markers, and differentiation potential in vitro and in vivo. Most importantly, we show that corrected FA-specific iPS cells can give rise to hematopoietic progenitors of the myeloid and erythroid lineages that are phenotypically normal, i.e. disease-free. These data offer proof-f-concept that iPS cell technology can be used for the generation of disease-corrected, patient-specific cells with potential value for cell therapy applications.

Similares en LA Referencia